03-02-2021 | Cs
The GPCs have already asked the Government for information on bureaucratic barriers to the advancement of Aplidin development and requesting emergency procedures for health emergencies without compromise.
Inés Arrimadas has met with José María Fernández Sousa-Faro, president of PharmaMar, a Spanish company that develops a drug against COVID-19, Aplidin. The deputy and spokesperson for Science of the GPCs, Marta Martín, also participated in the meeting, and in it the president of the liberal party expressed that “it is important that drugs against COVID-19 are launched, we cannot miss opportunities that they would also be a milestone for Spain ”.
During the meeting, the president of PharmaMar reported on the advances in the research of this drug, which shows very encouraging data. Arrimadas has reiterated Citizens' support for innovation and R&D.
It should be remembered that the GPCs already registered an initiative requesting the Government for information on bureaucratic barriers to the advancement of Aplidin development, requesting in turn emergency procedures for health emergency situations without compromising security. The European Medicines Agency has been able to approve the development of vaccines against COVID-19 in record time, so to take advantage of the potential of the Spanish pharmaceutical and biotechnology industry we must have administrative procedures that accompany and promote this development, not that hinder it.